ISCCA Recommendations on Clinical, Physical Evidence on Survivorship and Caregivers’ Preference for Common In-Vivo Medication

Each year, physicians and pharmacists collaborate in nearly 2,500 clinical practice meetings across the United States to inform and support new guidelines for clinical trials, clinical trials design, and patient decision support. The goal of these meetings is to provide an optimal environment for advancing lifesaving research towards impactful clinical, translational, and societal outcomes. For this year’s review, the Society of General Internal Medicine (SGI) International Clinical Chemistry and Drug Directorate (ICD) released its 2019 recommendations.

The perspectives and workflows matched Quinlan’s ideal group for this review, which were derived from an in-depth understanding of clinical decision support and tool use.

Dr. Naveen Boehm, PhD, director of the Clinical Pharmacology Program and co-principal investigator of the Oral Pharmacopsych Rosetham Questionnaire I-1 Drug Repository, said the emphasis on oral drug professionals’ preferences for common drugs was broad and simple to encompass. In applying the above-referenced Vocational Conditionedness of Patients Division (VCD / VDB) meta-analyses, Dr. Boehm said recommendations for the pharmacists the submitted were reflective of a number of stakeholders.

Dr. Boehm cited incidence of suicidal ideation, use of cheap nonopioid medications, affordability of medications, and high-adverse drug events, among others, as reasons for the organization’s current recommendation. Dr. Boehm also cited counseling beliefs, activation behavior, medication tolerance, change of diagnosis in line with new clinical findings, voice bias, residual effects, and opioid dependence.

Dr. Boehm welcomed receiving feedback if the recommendations were thought to be important and incorporated into the meeting. He encouraged participants to reach out to him if interested.